Efforts to modernize Medicare are once again gathering momentum in the nation’s capital. The current debate centers around cutting costs for patients, while also encouraging drug innovation, research and development. Should the government be able to negotiate drug prices in Medicare? What can Congress do to lower costs for prescription drugs for seniors and people with disabilities? Can Medicare be improved to help patients access care and afford their medications?

The Hill newspaper gathered policymakers, pharmaceutical company representatives and patient advocates to talk about updating Medicare to ensure its beneficiaries get the care they need and deserve.

When

July 27, 2021, 1:00 PM EST

Speakers:

• Lisa Joldersma, Senior Vice President, Policy, Research and Membership, PhRMA
• Luke Greenwalt, Vice President, IQVIA Market Access Center of Excellence
• Ruud Dobber, EVP & President BioPharmaceuticals Business Unit, AstraZeneca
• Randall Rutta, CEO, National Health Council
• Dr. Meena Seshamani, Deputy Administrator and Director, Center for Medicare at Centers for Medicare & Medicaid Services